Cencora, Inc. (NYSE:COR) Chairman Sells $5,071,822.20 in Stock

Cencora, Inc. (NYSE:COR) Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Cencora Trading Down 0.3 %

NYSE COR opened at $234.47 on Friday. Cencora, Inc. has a 12 month low of $182.75 and a 12 month high of $247.66. The stock has a market capitalization of $46.77 billion, a P/E ratio of 25.65, a PEG ratio of 1.40 and a beta of 0.44. The firm’s 50-day moving average is $232.15 and its two-hundred day moving average is $230.87. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. During the same quarter last year, the company posted $2.92 EPS. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. On average, sell-side analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a $0.51 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.87%. Cencora’s payout ratio is presently 22.32%.

Hedge Funds Weigh In On Cencora

Several hedge funds have recently bought and sold shares of the company. Lake Street Advisors Group LLC grew its position in Cencora by 1.3% in the 3rd quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock valued at $769,000 after acquiring an additional 43 shares in the last quarter. Financial Advocates Investment Management increased its stake in Cencora by 4.7% during the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock worth $220,000 after buying an additional 44 shares during the period. Checchi Capital Advisers LLC lifted its holdings in Cencora by 2.2% during the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock worth $499,000 after buying an additional 48 shares in the last quarter. J.W. Cole Advisors Inc. boosted its position in Cencora by 1.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company’s stock valued at $826,000 after buying an additional 48 shares during the period. Finally, Valeo Financial Advisors LLC grew its stake in shares of Cencora by 3.4% in the second quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company’s stock worth $353,000 after acquiring an additional 51 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Evercore ISI lowered their price target on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Robert W. Baird lowered their price objective on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Leerink Partners cut their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Finally, Bank of America restated a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $259.44.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.